Ionis Pharmaceuticals, Inc. IONS
NASDAQ · United States · Health Technology
$44.98+0.33 (+0.74%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
The latest trades reveal where Wood sees opportunity
Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investors is how well the current valuation lines up with the sales its business is generating and may be able to support over time. The stock is down about 45.0% year to date. This puts a sharp spotlight on whether today's market value still lines up with what Ionis can justify through its sales...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.